Cash & Equivalents
Edwards Lifesciences Cash & Equivalents decreased by 16.7% to $2.45B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 22.3%, from $3.15B to $2.45B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows an upward trend with a 19.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase signals improved liquidity and financial flexibility, while a decrease may indicate heavy capital expenditure, debt repayment, or aggressive share buybacks.
Detailed definition
Represents the most liquid assets on the balance sheet, including physical currency and short-term investments with matu...
Peer comparison
Large-cap technology peers often maintain high cash balances to fund rapid innovation and offset the cyclical nature of consumer electronics.
cash_and_equivalentsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.33B | $1.52B | $862.80M | $1.04B | $1.20B | $1.25B | $769.00M | $876.40M | $1.05B | $1.41B | $1.14B | $1.23B | $1.66B | $3.68B | $3.05B | $3.15B | $3.29B | $2.69B | $2.94B | $2.45B |
| QoQ Change | — | +14.6% | -43.2% | +20.0% | +16.2% | +4.1% | -38.6% | +14.0% | +19.5% | +35.0% | -19.1% | +7.4% | +34.9% | +122.1% | -17.3% | +3.4% | +4.5% | -18.1% | +9.0% | -16.7% |
| YoY Change | — | — | — | — | -9.3% | -17.6% | -10.9% | -15.3% | -12.9% | +13.0% | +48.8% | +40.2% | +58.3% | +160.5% | +166.2% | +156.2% | +98.4% | -26.8% | -3.5% | -22.3% |
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Edwards Lifesciences's cash & equivalents?
- Edwards Lifesciences (EW) reported cash & equivalents of $2.45B in Q1 2026.
- How has Edwards Lifesciences's cash & equivalents changed year-over-year?
- Edwards Lifesciences's cash & equivalents decreased by 22.3% year-over-year, from $3.15B to $2.45B.
- What is the long-term trend for Edwards Lifesciences's cash & equivalents?
- Over 5 years (2020 to 2025), Edwards Lifesciences's cash & equivalents has grown at a 19.9% compound annual growth rate (CAGR), from $1.18B to $2.94B.
- What does cash & equivalents mean?
- Money in the bank and very short-term investments that can be turned into cash almost instantly.